Former Executive Vice President and Chief Medical Officer (10) · SELLAS Life Sciences Group, Inc. (SLS)

Nicholas Sarlis

A named executive officer of SELLAS Life Sciences in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$445,617

Salary $142,500Stock awards $0Bonus $47,804

FY2018: $783,304

3rd of 4 named executive officers at Sellas Life Sciences by FY2019 total.

4 named officers on file for SELLAS Life Sciences, FY2019

Nicholas Sarlis’s pay file — $29

  • 3 fiscal years of pay, line by line
  • SLS’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SELLAS Life Sciences’s whole pay program stands against its peers

  • SELLAS Life Sciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SLS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2020 (DEF 14A).

Free

Get Nicholas Sarlis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Nicholas Sarlis compensation by year

SELLAS Life Sciences Summary Compensation Table · all 3 fiscal years held
In US dollars, as SELLAS Life Sciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$438,889$373,742$142,500
Bonus$161,000$106,400$47,804
Stock awards$0$0$0
Option awards$0$253,154$54,601
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$17,003$50,008$200,712
Total$616,892$783,304$445,617

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SELLAS Life Sciences Group, Inc. DEF 14A filed April 23, 2020, accession 0001104659-20-049860, and prior-year filings.

How this page was built: the SELLAS Life Sciences Group, Inc. filed document, accession 0001104659-20-049860. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2020.

$617K
$783K
$446K
FY17
FY18
FY19
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option70,000—$5.24

Per the Outstanding Equity Awards at Fiscal Year-End table in SELLAS Life Sciences Group, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

SELLAS Life Sciences’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Angelos StergiouPresident and Chief Executive Officer$1,426,610
Barbara WoodExecutive Vice President, General Counsel and Corporate Secretary (6)$705,672
Nicholas Sarlis · this pageFormer Executive Vice President and Chief Medical Officer (10)$445,617
John BurnsVice President, Finance and Corporate Controller$436,727

The full SELLAS Life Sciences compensation record

free company brief

This page is one person within SELLAS Life Sciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the SELLAS Life Sciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SELLAS Life Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Nicholas Sarlis's compensation dossier · One-time report. No refunds.